QuantHealth vs Unlearn.AI
If your failure mode is buying breadth, 23 therapeutic areas and a headline 90 percent accuracy, without asking what validates it, this pair is a clean lesson in evidence posture. Both simulate trials before they run. QuantHealth's Large Real-World Drug Model is a general purpose foundation model trained on more than 350 million patients, spanning oncology, immunology, and cardiometabolic disease, with strong reported figures that are almost entirely vendor generated and carry no peer reviewed methodology or regulatory qualification. Unlearn.AI is the opposite trade: narrow, only where a disease specific digital twin generator exists, but its PROCOVA method holds a positive EMA qualification opinion, is published and patented with a public mathematical proof, and FDA CDER has stated it concurs. Pick breadth you must take on trust, or a bounded method a regulator has already vetted.
- Breadth is the commercial advantage: a general purpose model across a reported 23 therapeutic areas including oncology, immunology, and cardiometabolic disease, covering trial design, indication selection, drug repurposing, and probability of success, where Unlearn only operates where a disease specific generator exists.
- It reports scale and headline accuracy specifically, 88 percent for Phase 2 and 83.2 percent for Phase 3 predictions on a model trained across more than 350 million patients, and claims predictions without sponsor data.
- If your program spans indications with binary or time to event endpoints common in oncology and cardiovascular trials, QuantHealth's general model applies where Unlearn's EMA qualification, limited to continuous endpoints, does not.
- The regulatory standing is unique in this index: PROCOVA holds a positive EMA qualification opinion as an acceptable primary analysis approach for Phase 2 and 3 trials with continuous endpoints, and FDA CDER has stated it concurs, a regulator endorsing a method rather than clearing a device.
- The method is auditable from primary sources: published and patented, with a public mathematical proof and named authors, so a buyer or a regulator can verify it rather than trust a datasheet, which is why it could be qualified at all.
- Safety is solved by design, not policy: the team refused to use twins as external control arms and instead supplies only a prognostic covariate within a randomized trial, preserving randomization and bounding bias even when the model omits variables.
Side-by-Side
| Axis | Q QuantHealth |
U Unlearn.AI |
|---|---|---|
| AI Centrality | ||
| Autonomy and Oversight Model | ||
| Model and Technology Transparency | ||
| Clinical and Operational Evidence | ||
| AI Safety and PHI Stewardship | ||
| HIPAA and BAA Posture | ||
| Security Certifications and Trust Center | ||
| FDA and Regulatory Status | ||
| AI Governance and Bias Disclosure | ||
| EHR and Interoperability Depth | ||
| Deployment Model and Data Residency | ||
| Commercial Transparency | ||
| Setting and Specialty Coverage |
This is the index's clearest evidence posture contrast. Unlearn's claims sit in peer reviewed literature and a regulatory qualification, though several key demonstrations are simulations or retrospective applications rather than prospective use as the primary analysis of a completed registrational trial, and its EMA qualification is narrow to continuous endpoints. QuantHealth's figures, up to 90 percent accuracy and 31.4 million dollars in savings for an unnamed pharmaceutical partner, are vendor generated with no peer reviewed methodology located and no definition of how accuracy is measured or whether predictions were made before readout. Both share a governance risk worth naming: a model trained on historical data that predicts a non responder subgroup could narrow who a trial enrolls, shaping who the eventual therapy is studied in and labeled for. Neither publishes pricing.